Arima, Naoaki
Dr. Naoaki Arima joined CICS in June, 2015, and is working on finding novel pharmacological targets for diabetes. In 2012, he started working in diabetes research group in pharmacology research dept. at Tokyo New Drug Research Laboratories (KOWA Company, Ltd.). He carried out in vivo evaluation using type 2 diabetic animal models and in vitro evaluation using cells, isolated islet and so on. He received his Ph.D. (Pharmaceutical science) at Tohoku University in 2012, where he focused on researching lysophospholipids, especially lysophosphatidic acid (LPA) which attracted attention as a new lipid mediator. He investigated the role in the bone formation of LPA signaling and discovered the new function of LPA in bone formation.
Publications
Show
Inoue A, Ishiguro J, Kitamura H, Arima N, Okutani M, Shuto A, Higashiyama S, Ohwada T, Arai H, Makide K, Aoki J
TGFα shedding assay: an accurate and versatile method for detecting GPCR activation.
Arima N, Inoue A, Makide K, Nonaka T, Aoki J
Surface loops of extracellular phospholipase A(1) determine both substrate specificity and preference for lysophospholipids.
Yukiura H, Hama K, Nakanaga K, Tanaka M, Asaoka Y, Okudaira S, Arima N, Inoue A, Hashimoto T, Arai H, Kawahara A, Nishina H, Aoki J
Autotaxin regulates vascular development via multiple lysophosphatidic acid (LPA) receptors in zebrafish.
Inoue A, Arima N, Ishiguro J, Prestwich GD, Arai H, Aoki J
LPA-producing enzyme PA-PLA₁α regulates hair follicle development by modulating EGFR signalling.
Makide K, Kano K, Kitamura H, Arima N, Aoki J
[Lysophospholipid mediators].
Tanpakushitsu Kakusan Koso. 2009;54(1):29-39 - PMID:
19195223
Kano K, Arima N, Ohgami M, Aoki J
LPA and its analogs-attractive tools for elucidation of LPA biology and drug development.
